Mapping geographic inequalities in oral rehydration therapy coverage in low- and middle-income countries, 2000–17

WIENS, Kirsten, REINER, Bobby, A LINDSTEDT, Paulina, KHATAB, Khaled <http://orcid.org/0000-0002-8755-3964> and IAIN HAY, Simon

Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/27008/

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

Published version


Copyright and re-use policy

See http://shura.shu.ac.uk/information.html
Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17

Local Burden of Disease Diarrhoea Collaborators

Summary

Background Oral rehydration solution (ORS) is a form of oral rehydration therapy (ORT) for diarrhoea that has the potential to drastically reduce child mortality; yet, according to UNICEF estimates, less than half of children younger than 5 years with diarrhoea in low-income and middle-income countries (LMICs) received ORS in 2016. A variety of recommended home fluids (RHF) exist as alternative forms of ORT; however, it is unclear whether RHF prevent child mortality. Previous studies have shown considerable variation between countries in ORS and RHF use, but subnational variation is unknown. This study aims to produce high-resolution geospatial estimates of relative and absolute coverage of ORS, RHF, and ORT (use of either ORS or RHF) in LMICs.

Methods We used a Bayesian geostatistical model including 15 spatial covariates and data from 385 household surveys across 94 LMICs to estimate annual proportions of children younger than 5 years of age with diarrhoea who received ORS or RHF (or both) on continuous continent-wide surfaces in 2000–17, and aggregated results to policy-relevant administrative units. Additionally, we analysed geographical inequality in coverage across administrative units and estimated the number of diarrhoeal deaths averted by increased coverage over the study period. Uncertainty in the mean coverage estimates was calculated by taking 250 draws from the posterior joint distribution of the model and creating uncertainty intervals (UIs) with the 2.5th and 97.5th percentiles of those 250 draws.

Findings While ORS use among children with diarrhoea increased in some countries from 2000 to 2017, coverage remained below 50% in the majority (62.6%; 12,417 of 19,823) of second administrative-level units and an estimated 6,519,000 children (95% UI 5,254,000–7,733,000) with diarrhoea were not treated with any form of ORT in 2017. Increases in ORS use corresponded with declines in RHF in many locations, resulting in relatively constant overall ORT coverage from 2000 to 2017. Although ORS was uniformly distributed subnationally in some countries, within-country geographical inequalities persisted in others; 11 countries had at least a 50% difference in one of their units compared with the country mean. Increases in ORS use over time were correlated with declines in RHF use and in diarrhoeal mortality in many locations, and an estimated 52,230 diarrhoeal deaths (36,910–68,860) were averted by scaling up of ORS coverage between 2000 and 2017. Finally, we identified key subnational areas in Colombia, Nigeria, and Sudan as examples of where diarrhoeal mortality remains higher than average, while ORS coverage remains lower than average.

Interpretation To our knowledge, this study is the first to produce and map subnational estimates of ORS, RHF, and ORT coverage and attributable child diarrhoeal deaths across LMICs from 2000 to 2017, allowing for tracking progress over time. Our novel results, combined with detailed subnational estimates of diarrhoeal morbidity and mortality, can support subnational needs assessments aimed at furthering policy makers’ understanding of within-country disparities. Over 50 years after the discovery of this simple, cheap, and life-saving therapy, large gains in reducing mortality could still be made by reducing geographical inequalities in ORS coverage.

Funding Bill & Melinda Gates Foundation.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Oral rehydration solution (ORS) is a simple treatment that can be prepared and used at home to prevent mortality due to dehydration and undernutrition in children with diarrhoea. This intervention is especially suitable in locations where intravenous fluids are scarce or unavailable, and replaces indiscriminate and unnecessary use of antibiotics to treat diarrhoea. ORS was discovered more than 50 years ago when a physician in Dhaka, Bangladesh, found that treating patients with cholera with glucose-electrolyte solutions in equivalent amounts to fluid losses could prevent the need for intravenous liquids in 80% of patients. Shortly thereafter, its ability to prevent dehydration was shown in a trial in Kolkata, India, and during a cholera outbreak among Bangladeshi refugees in India. Since then,
Articles refer to treatment with ORS or RHF. Despite its use, rehydration therapy (ORT) became the phrase used to describe the use of oral rehydration solution (ORS) and oral rehydration therapy in addition to ORS, and oral rehydration fluids (RHF), with the necessary inclusion of “coverage”. This returned 229 total studies, seven of which presented or reviewed national-level estimates of ORS coverage globally or across multiple countries, and 26 of which estimated ORS or RHF coverage subnationally in select countries. None of these studies, however, estimated ORS or RHF coverage subnationally across multiple regions or used geospatial modelling techniques to estimate ORS or RHF coverage in locations with sparse data.

To our knowledge, this study presents the first high-resolution subnational estimates of the proportion and absolute number of children younger than 5 years with diarrhoea who received ORS or RHF in low-income and middle-income countries (LMICs) from 2000 to 2017. This work supports the examination of how patterns of coverage have changed over time since the establishment of the Millennium Development Goals in 2000, the identification of subnational areas in need of targeted interventions, and the stratification of oral rehydration therapy coverage into ORS and RHF estimates. We used Bayesian geostatistical modelling techniques and an extensive geolocated dataset to produce these estimates. Wherever possible, we tailored these methods to take into account national or subnational factors that might contribute to variation in ORS coverage, using spatially resolved covariates to estimate for areas with sparse data. These techniques produced estimates on a continuous continent-wide surfaces, which we aggregated to policy-relevant administrative units. We show that ORS use has increased over time, and that increases in ORS use often corresponded to declines in RHF use to treat diarrhoea and in diarrhoeal mortality rate. We estimate that scaling up of ORS treatment over the study period prevented an estimated 52 230 deaths (95% CI 46 910–68 860) across LMICs in 2017. Despite progress, coverage of ORS (ie, the proportion of children with diarrhoea who received ORS) remained below 50% in many locations where diarrhoea prevalence and mortality rates remain high. Importantly, we also show that while within-country geographical inequalities declined over time, large disparities remained in multiple countries with high diarrhoeal burden, including subnational areas of Colombia, Peru, Nigeria, and Sudan.

WHO, UNICEF, and the US Centers for Disease Control and Prevention have promoted ORS as an essential medicine to treat diarrhoea, the third leading cause of death in children younger than 5 years of age worldwide. In the 1980s, in response to low ORS coverage (ie, the proportion of children with diarrhoea who received ORS), WHO promoted the use of so-called recommended home fluids (RHF) in addition to ORS, and oral rehydration therapy (ORT) became the phrase used to refer to treatment with ORS or RHF. Despite its inclusion in the WHO Essential Medicines List and Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea, coverage of ORS remains low. According to UNICEF surveys, only 34% of children younger than 5 years in low-income and middle-income countries (LMICs) in 2000 received ORS to treat diarrhoea; in 2016, the proportion increased to 44%, yet the majority remained untreated.

The efficacy of ORS and RHF in preventing child mortality relies on proper preparation of the solutions, which can vary depending on the resources available to a household. ORS is most commonly sold as premade packets with standardised sodium and glucose content, which need to be dissolved in 1 L of clean water and can then be stored for about 48 h. The cost of these packets varies by country; in Uganda, a single packet costs approximately 500 Ugandan shillings (about US$0.15), and in Nigeria in 2012, the cost of three packets ranged from $0.63 to $4.38 depending on location. By contrast, RHF can be made with household items and therefore can be less costly and more widely accessible. The composition of RHF varies by country and can include carefully measured sugar and salt added to clean water, or it can simply include plain juice, rice water, tea, or coconut water. A meta-analysis study in 2010 estimated that 100% coverage of ORS could prevent...
93% of diarrhoeal deaths, yet found insufficient evidence on the effectiveness of RHF in preventing mortality, probably due to the broad range in RHF composition.¹⁴

To understand trends in diarrhoeal deaths and ORT coverage across space and time, it is crucial to analyse ORS and RHF treatment separately. A study in Ethiopia found subnational geographical variation in ORT coverage, which was driven primarily by differences in wealth.¹⁷ A recent study including data from 88 LMICs showed an 8 percentage-point difference in ORT coverage on average between the wealthiest and poorest household quintiles, which was low compared with other interventions such as improvements to water and sanitation.¹⁶ These studies, however, did not analyse ORS and RHF separately and might have underestimated variation. Other studies have shown that ORS use can vary broadly between countries, even between those sharing borders.¹¹,¹⁷ Additionally, studies have shown differences in ORS use between urban and rural populations in Kenya¹⁸ and Mexico.¹⁹ These findings suggest that there are subnational drivers of variation in ORS coverage, and that these drivers can differ between geographical regions. Moreover, previous studies showed subnational variation in diarrhoeal deaths and overall deaths in children younger than 5 years.²⁰–²² some of which might be driven by subnational variation in ORS given its efficacy in reducing child mortality.

Furthermore, policies related to diarrhoea treatment set at the national level do not affect all subnational areas equally, and interventions are often implemented at the subnational level, such as those currently done in Nigeria and India.²³–²⁵ Local-level estimates of ORS and RHF coverage are thus needed to identify vulnerable subpopulations most in need of increased efforts to prevent child mortality. Yet, to our knowledge, no study has estimated ORS coverage subnationally across multiple regions or has used geospatial modelling techniques to estimate ORS coverage in locations with sparse data, and no study has compared ORS coverage to patterns in RHF coverage.

Our aim in this study was to estimate the proportions of children with diarrhoea who were treated with ORS and RHF (ie, ORS and RHF coverage, respectively) over space and time in LMICs and examine geographical inequalities within countries. Here we present, to our knowledge, the first maps of ORS or RHF coverage for second administrative-level units (eg, districts, counties; henceforth referred to as units) in LMICs. We present both relative quantities (proportion of children) and absolute quantities (number of children), as these measures have distinct policy implications. We conclude by highlighting countries with some of the broadest differences in coverage across subnational units, which also have high diarrhoeal burdens and high subnational variation in mortality.

Methods

Definitions

For this study, ORS was defined as a pre-packaged electrolyte solution containing glucose or another form of sugar or starch, as well as sodium, chloride, potassium, and bicarbonate.¹⁴ Survey questions did not allow us to separate RHF into their different formulations; therefore, RHF were defined as all possible home fluid alternatives, including sugar-salt solution, cereal-salt solution, rice-water solution, and additional fluids, such as plain water, juice, tea, or rice water.¹⁴ To account for this variation, we adjusted all non-standard RHF definitions to the most common or standard definition across all surveys, using logistic regression to determine adjustments (appendix 1 p 3). ORT was defined as treatment with either ORS, RHF, or both. Coverage was defined as the proportion of children younger than 5 years of age with diarrhoea who received ORS, RHF, or ORT. Diarrhoea was defined as three or more abnormally loose or watery stools within a 24-h period.

Data

We compiled 385 household surveys (including Demographic and Health Surveys, Multiple Indicator Cluster Surveys, and other country-specific surveys) representing 3609000 children with diarrhoea in 94 LMICs from 2000 to 2017, with geocoded information from 120742 coordinates corresponding to survey clusters and 14055 subnational polygon boundaries where point-level referencing was not available (appendix 1 p 4). We included surveys that asked if children younger than 5 years with diarrhoea received any kind of ORT, allowed for geolocation below the country level, and were representative of the populations in which they were conducted. We included surveys for countries classified as low income or middle income on the basis of their Socio-demographic Index (SDI) quintile: low SDI, low-middle SDI, or middle SDI.²⁶ SDI, developed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), indicates the level of development based on a country’s average education, fertility, and income, and is on a scale of 0 to 1.²⁶ Only LMICs with relevant and available underlying data were included in subsequent analyses, and island nations with fewer than 1 million inhabitants were excluded (appendix 1 p 4). This study complied with the Guidelines for Accurate and Transparent Health Estimates Reporting recommendations (appendix 1 pp 85–86).²⁷ Further details on data inclusion, coverage, and validation can be found in appendix 1 (pp 4, 8).

We compiled 15 spatial covariates that were indexed at the subnational level for all 94 countries included in the study and that had conceivable relationships with ORT, which were used as predictors in our model. Covariates related to urbanicity or access to cities were night-time lights, population, urban or rural location, urban proportion of the location, and access to cities. Covariates related to child health, support, and nutrition were
prevalence of under-5 stunting, prevalence of under-5 wasting, ratio of child dependents (ages 0–14 years) to working adults (ages 15–64 years), number of children younger than 5 years per woman of childbearing age, number of people whose daily vitamin A needs could be met, and maternal education. Covariates related to environmental factors that might affect diarrhoeal burden, which might in turn affect ORS supply, were aridity, distance from rivers or lakes, elevation, and irrigation. We also included the Healthcare Access and Quality Index37 and the proportion of pregnant women who received four or more antenatal care visits as national-level covariates. We filtered these covariates for multicollinearity within each modelling region (appendix 1 p 5) using variance inflation factor (VIF) analysis with a VIF threshold of 3.28 Detailed covariate information can be found in appendix 1 (p 5).

Statistical analysis
Analyses were done using R version 3.5.0. ORS, RHF, and ORT coverage were modelled separately using a Bayesian model-based geostatistical framework. Briefly, this framework uses a spatially and temporally explicit hierarchical logistic regression model to predict coverage in all locations, assuming that points that are closer together in space and time and that have similar covariate patterns have similar coverage. Potential non-linear relationships between covariates and coverage were incorporated through the use of a stacked generalisation technique.29 Posterior distributions of all model parameters and hyperparameters were estimated using the statistical package R-INLA (version 19.05.30.9000).30,31 Uncertainty in the mean coverage estimates was calculated by taking 250 draws from the posterior joint distribution of the model, and each point value is reported with an uncertainty interval (UI), which represents the distribution of the model, and each point value is reported calculated by taking 250 draws from the posterior joint distribution of the model, and each point value is reported. We additionally did a sensitivity analysis of these results by halving and doubling the estimated lives that could be saved with ORS treatment44 (appendix 1 pp 82–83).

Role of the funding source
This research was supported by the Bill & Melinda Gates Foundation. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
In all years from 2000 to 2017, we found both between-country and within-country variation in the proportion of children younger than 5 years with diarrhoea who received ORT. In general, ORS coverage was highest in south Asia, east Asia, central America, and southern sub-Saharan Africa, and lowest in central sub-Saharan Africa, parts of western and eastern sub-Saharan Africa, the Middle East, and South America (figure 1). Within these regions, some countries had fairly uniform subnational distribution of ORS across units, such as Zimbabwe in 2017, where coverage ranged from 35.1% (95% UI 11·8–66·6) in Chivi district, Masvingo province, to 44–6% (16·2–76·7) in Mazowe district, Mashonaland Central province. Other countries had notable subnational variation, such as Peru in 2017, where coverage ranged from 16·1% (12·1–20·6) in Azángaro province, Puno region, to 45·2% (38·2–51·5) in Trujillo province,
Figure 1: Proportion of children younger than 5 years with diarrhoea who received ORT at the second administrative-unit level, 2000 and 2017

Mean proportion of children with diarrhoea who received ORS in 2000 (A) and 2017 (B) or who received RHF in 2000 (C) and 2017 (D). All countries are aggregated to second administrative units. Maps reflect administrative boundaries, land cover, lakes, and population. Dark grey grid cells were classified as barren or sparsely vegetated and had fewer than ten people per 1 km × 1 km grid cell; light grey countries were not included in these analyses. ORS=oral rehydration solution. ORT=oral rehydration therapy. RHF=recommended home fluids.
La Libertad region (figure 1B). In terms of absolute coverage, RHF coverage was lower and more evenly distributed in Peru in 2017, with coverage ranging from 5.0% (2.9–8.5) in Coronel Portillo province, Ucayali, to 19.7% (12.3–28.9) in Daniel Alcides Carrión province, Pasco (figure 1D). Across all LMICs, ORS coverage remained below 50% in 62.6% (12,417 of 19,823) of units in 2017.

Although most changes were small, we found that ORS coverage increased while RHF coverage decreased between 2000 and 2017 in many locations (figure 1). We found significant increases in ORS coverage nationally and subnationally in Rwanda, Vietnam, Bolivia, Cambodia, and India (figure 1; appendix 1 p 75; appendix 2 pp 1–8, 25–1615), and significant declines in RHF coverage in Rwanda, Burundi, Bolivia, Niger, Chad, and India (figure 1; appendix 1 p 76; appendix 2 pp 9–16, 1616–3206). In Rwanda, ORS coverage increased from 12.0% (95% UI 9.8–14.6) to 33.9% (22.9–45.4), with an annualised rate of change (AROC) of 10.7% (3.2–17.6). At the same time, RHF coverage decreased from 28.1% (16.1–41.6) to 10.7% (3.3–25.8), with an AROC of −2.8% (−28.3 to 19.7). Increases in ORS, as measured by AROC, were significant (ie, 95% UIs did not include 0) in 27 of Rwanda’s 30 units, while overall ORT coverage remained constant (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797). Kyrgyzstan, Yemen, and Liberia saw the largest increases in RHF coverage; however, uncertainty around these estimates was high, and only Yemen saw significant increases in RHF use (appendix 1 p 76; appendix 2 pp 9–16). Sudan and South Sudan were the only countries where AROC in ORS coverage declined substantially, with coverage decreasing from 32.3% (26.5–38.3) to 19.7% (14.6–25.8) in Sudan and from 52.0% (41.6–62.2) to 48.4% (37.6–59.5) in South Sudan. Declines were significant in eight of Sudan’s 80 units and four of South Sudan’s 45 units (figure 1; appendix 1 p 75; appendix 2 pp 1–8, 25–1615).

In 2017, the highest number of children with diarrhoea who remained untreated by ORS were in parts of eastern sub-Saharan Africa, north Africa, south Asia, and southeast Asia (figure 2). In 2000, it was estimated that approximately 6,668,000 children (95% UI 5,330,000–7,673,000) across the 94 LMICs included in this study were untreated with either ORS or RHF, out of a total of 12,873,000 children (12,344,000–13,471,000) with diarrhoea. Although prevalence of untreated children has declined, a substantial number remain in need of treatment; in 2017, we estimated 6,519,000 children (95% UI 5,254,000–7,733,000) with diarrhoea did not receive either ORS or RHF treatment, out of a total of 13,343,000 children (12,709,000–13,944,000) with diarrhoea, and this burden varied substantially within many countries (figure 2).

In addition to the results presented here, the full array of our model outputs for ORS, RHF, or ORT (either ORS or RHF) is provided in appendix 1 (pp 28–36) and is publicly available online, and can be further explored at various spatial levels via a user-friendly visualisation tool.

We found that inequality in ORS coverage, as measured by the Gini coefficient, decreased in the majority (63 [67%]) of countries from 2000 to 2017. In particular, although there were nine countries (Afghanistan, Cambodia, Cameroon, Côte d’Ivoire, Equatorial Guinea, Guinea, Iraq, Mali, and Mauritania) in 2000 whose Gini coefficient was greater than 0.15, only Afghanistan and Cameroon had coefficients above 0.15 in 2017.

Absolute percentage-point differences between units with the highest and lowest ORS coverage declined in 40 countries, with notable decreases in Equatorial Guinea, Central African Republic, Iraq, Mongolia, Myanmar, and Sierra Leone (figure 3). Absolute inequalities increased in more than half (54 [57%]) of LMICs, with notable increases in Jordan, Colombia, Uzbekistan, Afghanistan, Bolivia, Turkmenistan, Palestine, Benin, and Madagascar (figure 3). By contrast, within-country absolute geographical inequalities in RHF coverage declined in most (55 [59%]) countries, with notable exceptions in Yemen and Tajikistan (appendix 1 p 79).

Analysis of relative deviation from the country mean revealed that 11 LMICs (Afghanistan, Benin, Cameroon, Democratic Republic of the Congo, Colombia, Ethiopia, Guinea, Jordan, Nigeria, Sudan, and Uganda) had at least 50% relative deviation in one of their units in ORS use in 2017 (figure 3). Additionally, as mean national-level ORS coverage increased over time in most (76 [81%]) countries (appendix 1 p 78), within-country relative differences in ORS coverage also declined in 64 (68%) LMICs, with greater than 50% declines in relative deviation in Central African Republic, Equatorial Guinea, Iraq, Mali, Cambodia, Ethiopia, Niger, Senegal, Kyrgyzstan, Togo, Democratic Republic of the Congo, and Côte d’Ivoire (figure 3). Exceptions to this pattern, where relative differences increased more than 20%, included Jordan, Benin, Madagascar, Yemen, Sudan, Suriname, Guatemala, Turkmenistan, and Bolivia. Furthermore, as mean national-level RHF coverage declined over time in most (69 [73%]) countries, within-country relative inequalities in RHF coverage declined in 45 (48%) countries (appendix 1 p 78). In 2017, relative inequalities in RHF coverage remained highest in North Africa and the Middle East (appendix 1 p 78).

We found that mean ORS coverage was less than 50% in 12 of 14 countries where diarrhoeal mortality in 2017 was greater than two children per 1000 (appendix 2 pp 1–8). Furthermore, we found that ORS coverage was negatively correlated with RHF coverage over time in 56–6% (10,786 of 19,064) of units and was negatively correlated with diarrhoeal mortality over time in 74–7% (14,241 of 19,064) of units (appendix 1 p 81).
Figure 2: Number of children younger than 5 years with diarrhoea who did not receive ORT at the second administrative-unit level, 2000 and 2017

Number of children younger than 5 years with diarrhoea who did not receive ORS in 2000 (A) and 2017 (B) or did not receive ORT (either ORS or RHF) in 2000 (C) and 2017 (D). Countries are aggregated to second administrative units. Maps reflect administrative boundaries, land cover, lakes, and population. Dark grey grid cells were classified as barren or sparsely vegetated and had fewer than ten people per 1 km × 1 km grid cell; light grey countries were not included in these analyses. ORS=oral rehydration solution. ORT=oral rehydration therapy. RHF=recommended home fluids.
To illustrate how our maps can be used to estimate the number of diarrheal deaths that were averted by changes in ORS coverage, we did a counterfactual analysis using a previous estimate that 75% ORS coverage could reduce diarrheal deaths by 69%. This estimate is based on a systematic review of three quasi-experimental studies with small sample sizes and that did not adjust for confounding variables (eg, stunting) to examine the risk of death in the absence of ORS treatment; thus, the results of this analysis should be interpreted with some caution. We found that of the 526,800 diarrheal deaths (95% UI 485,300–568,900) estimated to have occurred in 2017 in children younger than 5 years across the 94 LMICs included in our analysis, an estimated 299,900 deaths (274,000–324,300) could be attributable to lack of treatment with ORS. We also estimated that increase in ORS coverage during the study period prevented an additional 52,230 deaths (36,910–68,860). Nigeria, India, Ethiopia, Pakistan, Chad, and Madagascar contained units with high numbers of deaths attributable to lack of ORS treatment in 2017; however, these countries also contained units with the highest numbers of deaths averted by improved ORS coverage in 2017 (figure 4). By contrast, an estimated 4850 deaths (2200–10,080) globally were due to declines in ORS coverage, with some of the highest numbers of deaths averted attributable to worsening coverage in units of Sudan, South Sudan, and Pakistan (figure 4). Some of the highest rates of deaths averted were in units of Sierra Leone, where 0–9 deaths (0·2–1·9) were averted per 1000 children in Kambia district, Northern Province (figure 4), corresponding to 67 lives (18–141) saved in 2017 in this district alone.

In a sensitivity analysis, we found that, while the geographical patterns in deaths averted remained largely unchanged, the absolute number of averted deaths changed substantially in some places (appendix 1 pp 82–83). Reducing the percentage of diarrheal deaths attributable to lack of ORS from 69% to 35% reduced the total number of deaths attributable to lack of ORS by 20%.

For ISO codes see https://www.iso.org/obp/ui
coverage in 2017 from 299 900 (95% UI 274 000–324 300) to 143 360 (130 400–156 000), the estimated total deaths averted by increase in ORS coverage from 52 230 (36 910–68 860) to 22 760 (15 600–30 650), and the averted deaths in Kambia district, Sierra Leone, from 67 (18–141) to 26 (8–53; appendix 1 p 82).

Figure 4: Averted child diarrhoeal deaths attributable to increased ORS coverage from 2000 to 2017 (A) Number of deaths in children younger than 5 years attributable to lack of ORS treatment in 2017. (B) Number of deaths in children younger than 5 years in 2017 averted by and attributable to changes in ORS coverage between 2000 and 2017. (C) Number of deaths per 1000 children younger than 5 years in 2017 averted by and attributable to changes in ORS between 2000 and 2017. Maps reflect administrative boundaries, land cover, lakes, and population. Dark grey grid cells were classified as barren or sparsely vegetated and had fewer than ten people per 1 km × 1 km grid cell; light grey countries were not included in these analyses. ORS=oral rehydration solution.
Finally, to illustrate how these maps can be used to identify children in need, we present side-by-side maps of diarrhoeal mortality, ORS coverage, and RHF coverage at the unit level for three countries—Colombia, Nigeria, and Sudan—that had subnational locations with higher-than-average mortality rates and lower-than-average ORS coverage (figure 5). In Colombia, ORS and RHF coverage were lowest in the southern Amazonas region, where diarrhoeal burden was highest. In Nigeria, ORS coverage was lowest in the northern region, where diarrhoeal burden was highest. In Sudan, RHF remains widely used to treat diarrhoea, and there was not a clear trend between ORS, RHF, and diarrhoea distributions, but distinct areas in Darfur, in the southeast of the country, had high diarrhoeal mortality and particularly low ORS coverage. To illustrate that this pattern was not present everywhere, we also present results for Peru, where ORS coverage was relatively high in the Amazon Basin rainforests, which is where diarrhoeal mortality was also highest. There were gaps in coverage in the mountainous and arid regions of central and south Peru, where diarrhoeal mortality was lower (figure 5).

**Discussion**

The discovery that led to the development of ORS as treatment for diarrhoea was hailed as “potentially the most important medical advancement of the century”. More than 50 years later, ORS is recognised as an important treatment for childhood diarrhoea, as well as a crucial component in treating other forms of dehydration, including dehydration-induced kidney injury and Ebola virus disease. By providing high-resolution estimates of the use of different forms of ORT—ORS, RHF, and either ORS or RHF—in children younger than 5 years with diarrhoea in LMICs, this study examines where uptake has occurred and which places stand to gain the most. While we show increases in ORS coverage in many locations, it is striking that these increases have been so incremental, given the importance and simplicity of this intervention. These slow changes are reflected in the relatively low number of total deaths estimated to have been averted by increases in ORS coverage between 2000 and 2017, and the substantial number of children with diarrhoea that remained untreated in 2017. ORS coverage remains below 50% in the majority (62·6%) of second administrative units, and there are various locations with high diarrhoeal mortality rates where geographical inequalities in ORS coverage are high. These areas need to be targeted with improved efforts to increase access to and awareness of this life-saving treatment.

We also show that increases in ORS coverage over time were correlated with declines in RHF coverage in many locations. It is possible that these results represent shifts over time in diarrhoea treatment, which might have contributed to declines in diarrhoeal mortality in these locations; ORS has shown effectiveness in preventing child mortality, whereas the effect of RHF on child mortality is unclear. However, if the rates of decline in RHF exceeded the rates of increase in ORS in some locations, this could have left a proportion of children...
completely untreated and in need of targeted interventions to prevent diarrhoeal mortality. These results further highlight the importance of reaching these vulnerable populations with targeted interventions to improve ORS coverage. It is important to note that there were also locations where there was apparently no relationship between ORS coverage and diarrhoeal mortality over time. This could, in part, be attributed to other risk factors that affect diarrhoeal mortality, which we did not take into account in this analysis.

Our estimates are comparable with previously published estimates at the national level.2,11 We show notable differences in ORS coverage between countries in the same region (eg, Senegal vs Sierra Leone), consistent with a previous review.8 We show that ORS use has increased over time, with greater uptake in some regions compared with others (eg, south Asia vs the Horn of Africa), which is consistent with the conclusions of UNICEF’s 2016 report.1,4 We also show that the rates of increase in ORS coverage and decrease in RHF coverage were modest and that uncertainty in these estimates was high, which is consistent with previous studies that showed no substantial increases in ORT coverage between 1990 and 200143 or between 1996 and 2003.44 We also show that relative and absolute geographical inequalities in ORS coverage declined over time in many countries, which is in contrast with a previous study that showed that absolute inequalities in ORT have remained the same over time in all but three LMICs.16 There are numerous methodological differences between that study and ours; most importantly, the previous study did not separate the effect of ORS from that of RHF. As we show, analysis of ORT (a combined variable) masks spatial and temporal variation in ORS and RHF.

We are surprised to see low use of ORS after so many years of programmes in many countries, especially those with high diarrhoeal burden. Ensuring access to ORS treatment is not only important for treating existing diarrhoea cases, but also in preparing for outbreaks and having supplies ready for emergencies. Moreover, educating caregivers on the causes of diarrhoea mortality—and how ORS can prevent those child deaths—is essential to ensure sustainable uptake. To address shortfalls in coverage, it will be essential to examine the root causes specific to each location. Previous studies have shown that challenges in using ORS include doctor and patient knowledge about ORS; ORS supply, cost, and taste; and access to clean water.2,3,5,6 Studies have also shown that improvements in ORS coverage can be driven by changes in government policies, media campaigns, and community culture and beliefs.2,3,5-8 According to our results, Sierra Leone had some of the highest ORS coverage in western sub-Saharan Africa in 2017. Sierra Leone has previously been described as an example of how community mobilisation can promote access to and awareness of ORS, even after a devastating civil war.2,9 Our results also suggest that promotion of RHF over ORS might negatively affect ORS use and that locations with high RHF use, such as Sudan, can have very low ORS coverage. A previous study has similarly shown that inconsistent and unclear diarrhoea treatment recommendations present challenges in Sudan and Somalia and might have had implications for the recent cholera epidemic in Yemen.48 By determining key country-specific drivers of low uptake and subnational inequalities, including various social, cultural, political, and economic factors that might inhibit proper coverage, successful interventions such as those in Sierra Leone could be adapted and applied to similar contexts.

Our study has several limitations. Although we constructed a large database of geolocated ORT coverage data, spatial and temporal gaps remain, and data quality is likely to be variable by source, contributing to uncertainty in our estimates. Thus, results from zones of conflict and political instability, such as Yemen, Syria, Iraq, Afghanistan, and Pakistan, should be interpreted with caution. For RHF modelling, we included a broad range of RHF definitions in the survey data, and the RHF definitions in survey questionnaires do not always correspond to the actual solutions that governments have recommended. In addition, since the denominator of our input data was the proportion of children with diarrhoea (ie, diarrhoea prevalence), sample sizes were very small. Finally, heterogeneity within the data as well as amount of relevant available data varied between countries. Each of these factors probably contributed to uncertainty in our estimates, which varied by indicator and country (appendix 2).

As a further limitation, the modelling framework was optimised for prediction rather than causal inference, and there were overlaps between covariates used to estimate ORS, RHF, and diarrhoeal mortality, so we cannot make any conclusions about causal relationships between them. Additionally, we were unable to incorporate uncertainty into our estimates of the number of children with diarrhoea who were untreated because uncertainty from WorldPop datasets13 was not available. Furthermore, we fit our models using survey data, which depend on recall and are susceptible to biases that could be in the direction of increased or decreased coverage, depending on the context. Lastly, we mapped the reported use of ORS, yet use is not equivalent to proper preparation of the solution.47,48

Future studies should examine the factors that have affected ORS coverage, particularly those that have contributed to shortfalls in efforts to increase coverage, to inform future interventions and implementation studies. Future work should also further investigate coverage of zinc treatment, which has shown effectiveness in reducing undernourishment and diarrhoeal mortality in many countries.49 In addition, promoting zinc use has shown a secondary effect of increasing ORS use in some places,2,5 thus comprehensive approaches to overcome challenges to uptake and scaling up of coverage are warranted.50 Future work could investigate how missing data affect
estimates of ORS coverage and how to account for this, as well as how to incorporate differences between urban and rural populations into the analysis. In addition, we did not map ORS availability, but rather the prevalence of its use, and future studies could map availability distribution patterns. Future work should examine the co-distribution of different interventions to prevent childhood mortality from diarrhoea, such as the co-distributions of ORS, zinc, and access to clean water. Finally, as with any study that involves estimation, the availability and quality of input data influences the certainty of our estimates; as LMICs work to improve their cause-specific vital registration systems, analyses that incorporate diarrhoea-specific cause of death data in estimates of diarrhoea mortality would improve future updates to this work.

In conclusion, our results show that advancement in ORS coverage was slow from 2000 to 2017, and that within-country inequalities in ORS coverage persist in many LMICs. Depending on the local context, low levels of coverage might reflect challenges in access to ORS or the need for education on the efficacy of ORS in preventing diarrhoea mortality. Increased efforts are needed, particularly where childhood deaths from diarrhoea are high yet ORS coverage remains low; in 2017, 12 of 14 LMICs where diarrhoeal mortality exceeded two children per 1000 had less than 50% ORS coverage. The subnational scale of these mapped estimates can aid in identifying where gaps in coverage of this life-saving intervention remain, contributing to the UN Sustainable Development Goals’ commitment to address inequalities and leave no one behind.51 Our results indicate that scaling up of ORS coverage has been insufficient, and that new efforts to improve access are desperately needed.

Local Burden of Disease Diarrhoea Collaborators


Acknowledgements

This work was supported by the Bill & Melinda Gates Foundation, contracts 52626, 54631, 54787, and 56148, and Evolutionary Health Analysis (EHA) (AW, MK, KT, DJ, KJ, SP, and CS). The authors thanks the Global Burden of Disease 2017 and 30 Ladder working groups for their contributions to the analysis. The authors and editors at The Lancet are grateful for the help of the many staff members and volunteers who have contributed to the Global Burden of Disease 2017 and 30 Ladder and the development of this report.
ON, Canada; Centre for Community Medicine (M Bairwa), Department of Paediatrics (Prof R Lodha MD), Department of Psychiatry (Prof R Sagar MD), All India Institute of Medical Sciences, New Delhi, India; Department of Forensic Medicine and Toxicology (S M Bakkannavar MD), Centre for Bio Cultural Studies (Prof V Jha MD), Indian Council of Medical Research, New Delhi, India (Prof L Dandona); Department of Epidemiology and Preventive Medicine (P Chatterjee MD), Indian Council of Medical Research, New Delhi, India; Department of Public Health (Prof N Bedi), Gandhi Medical College Bhopal, Bhopal, India; Department of Physical Medicine and Rehabilitation (M Beheshti MD), New York University, New York, NY, USA; Social Determinants of Health Research Center (Ma Behzadifar PhD), Department of Epidemiology and Biostatistics (Me Behzadifar MSc), Department of Public Health (M Imani-Nasab PhD, S Noiraei Motaqli PhD), Lorestan University of Medical Sciences, Khorramabad, Iran; Department of Public Health (B Bekele MPH, H Y Hassan MPH), Mizan-Tepi University, Mizan Tefere, Ethiopia; Doctoral School of Health Sciences (B Bekele), University of Debrecen, Debrecen, Hungary; School of the Environment (Prof M L Bell PhD), Yale University, New Haven, CT, USA; Novello Department of Population Health (D A Bennett PhD, M A Karim MD, B Lacey PhD), Department of Zoology (M U G Kraemer PhD), Big Data Institute (C E Moore PhD), University of Oxford, Oxford, UK; Department of Public Health (D A Berbada MPH, M B Sorrie MPH, F G W/khawarit MPH), Faculty of Health and Community Medicine (I T Works MPH), Arba Minch University, Arba Minch, Ethiopia; Hubert Department of Global Health (R S Bernstein MD), Division of Cardiology (Prof J Shin MD), Emory University, Atlanta, GA, USA; Division of Global Health (R S Bernstein), University of South Florida, Tampa, FL, USA; Division of General Internal Medicine (A G Bhat MD), University of Massachusetts Medical School, Springfield, MA, USA; Department of Statistical and Computational Genomics (K Bhattacharyya MSc), National Institute of Biomedical Genomics, Kalyani, India; Department of Statistics (K Bhattacharyya), University of Calcutta, Kolkata, India; Department of Global Health (S Bhattacharji MD), Global Institute for Interdisciplinary Studies, Kathmandu, Nepal; Injury Division (S Bhaukuni MBB), The George Institute for Global Health (S Bhaukuni V), The George Institute for Global Health (S Bhaukuni), Transport and Road Safety Research Centre (R Biswas MSc, S Boufous PhD), School of Public Health and Community Medicine (S Kari PhD), School of Optometry and Vision Science (Prof K S Naidoo, Prof S Resnikoff MD), University of New South Wales, Sydney, NSW, Australia; Centre of Excellence in Women & Child Health (Prof Z A Bhutta), Division of Women and Child Health (J K Das MD), Aga Khan University, Karachi, Pakistan; Mario Negri Institute for Pharmacological Research, Ranica, Italy (B Bikbov MD); Ethiopian Public Health Institute, Addis Ababa, Ethiopia (B M Birhan MD); School of Nursing (B M Birhanu), Debre Tabor University, Debre Tabor; Ethiopia; School of Health Sciences (R Biswas), Swinburne University of Technology, Melbourne, VIC, Australia; Department of Veterinary Medicine (S Boholli PhD), Islamic Azad University, Kermanshah, Iran; University of Genoa, Genoa, Italy (N L Bragazzi PhD); Department of Biomedical Technologies (A N Briko MSc), Bauman Moscow State Technical University, Moscow, Russia; Department of Epidemiology and Evidence Based Medicine (Prof N I Briko DSc), A N Sennashko Department of Public Health and Healthcare (Prof M Jakovlevic PhD), I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Neuroscience Unit (G B Britton PhD), Institute for Scientific Research and High Technology Services, Panama City, Panama; Gorgas Memorial Institute for Health Studies, Panama City, Panama (G B Britton, F Castro MD, I Moreno Velásquez PhD, H Quintana PhD); Department of Community Medicine (Prof S Burungina Nagaraja MD), Employee State Insurance Post Graduate Institute of Medical Sciences and Research, Bangalore, India; Department of Health Care Management (Prof R Busse PhD), Technical University of Berlin, Berlin, Germany; School of Public Health and Health Systems (Z A Butt PhD), University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public Health (Z A Butt), Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan; Internal Medicine Department (Prof L A Cámara PhD), Hospital General Universitario de Navarra, Pamplona, Navarra, Spain; Buenos Aires, Argentina; Board of Directors (Prof L A Cámara), Argentine Society of Medicine, Buenos Aires, Argentina (Prof P R Valdez MEZ); Centre for Population Health Sciences (J Car), Nanyang Technological University, Singapore; Singapore: Department of Health Care (Prof R Cárdenas DSc), Metropolitan Autonomous University, Mexico City, Mexico; Research Unit on Applied Molecular Biosciences (Prof F Carvalho PhD, V M Costa PhD), Associated Laboratory for Green Chemistry (Prof E Fernandes PhD, N G M Gomes PhD), Department of Chemistry (N G M Gomes), EPUnit—Public Health Institute University Porto (A Ribiero PhD), University of Porto, Portugal; Epidemiology and Public Health Evaluation Group (C A Castañeda-Orjuela), Department of Public Health (Prof F P De la Hoz PhD), National University of Colombia, Bogota, Colombia; Division of Epidemiology and Communicable Diseases (P Chatterjee MD), Indian Council of Medical Research, New Delhi, India (Prof L Dandona); Department of Epidemiology and Preventive Medicine (K L Chin PhD, Prof Y Guo PhD), School of Public Health and Preventive Medicine (S Li PhD), The School of Clinical Sciences at Monash Health (S Zaman), Monash University, Melbourne, VIC, Australia; Melbourne Medical School (K L Chin), University of Melbourne, Parkville, VIC, Australia; Department of Pulmonary Medicine (Prof D J Christopher MD), Department of Endocrinology, Diabetes and Metabolism (Prof N Thomas PhD), Department of Nephrology (Prof S Varughese FRCP), Christian Medical College and Hospital, Vellore, India; Faculty of Biology (D Chu PhD), Hami National University of Medical and Economic Sciences, Xinjiang, China; Veterinary and Training Consortium on Emerging Diseases and Climate Change (C Cuelquichon MD), Peruvian University Cayetano Heredia, Lima, Peru; Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi (G Damiani MD), Department of Clinical Sciences and Community Health (Prof C La Vecchia MD), University of Milan, Milan, Italy;
Department of Physiotherapy and Occupational Therapy (M M Sisay), Nazareth-Slagelse-Ringedst Hospital, Slagelse, Denmark; Department of Ophthalmology (E Skådanes MD), Hwyl Da University Health Board, Llanelli, UK; Department of Infectious Diseases (A Sokhan PhD), Kharkiv National Medical University, Kharkiv, Ukraine; Department of Medicine (R Sozayajji), University of Calgary, Calgary, AB, Canada; Hull York Medical School (I N Soiyi), University of Hull, Hull City, UK; Division of Community Medicine (C T S Ungar MD), International Medical University, Kuala Lumpur, Malaysia; Nursing (A Sudaryo MPH), Muhammadiah University of Surakarta, Surakarta, Indonesia; Department of Public Health (A Sudaryanto), China Medical University, Taiwan; Health Economics (M Sultana), Deakin University, Melbourne, VIC, Australia; Department of Community Health (B F Sunguya PhD), Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Department of Criminology, Law, and Society (Prof B L Sykes PhD), University of California Irvine, Irvine, CA, USA; Department of Medicine (Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; Carlos III Health Institute (Prof R Tabarés-Seisdedos), Biomedical Research Networking Center for Mental Health Network, Madrid, Spain; Cancer Control Center (T Tabuchi MD), Osaka International Cancer Institute, Osaka, Japan; Axum College of Health Science, Mekelle, Ethiopia (D B Tadesse); Research and Development Center for Humanities and Health Management (J U Tarigan PhD), National Institute of Health Research & Development, Jakarta, Indonesia; Department of Public Health and Community Medicine (Prof R K Thakappan MD), Central University of Kerala, Kasaragod, India; Institute of Public Health (R Topor-Madry PhD), Jagiellonian University Medical College, Kraków, Poland; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland (R Topor-Madry); Department of Pathology and Legal Medicine (M R Tovani-Palone MD), University of São Paulo, Ribeirão Preto, Brazil; Modestum LTD, London, UK (M R Tovani-Palone); Department of Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, Vietnam; Molecular Medicine and Pathology (K B Tran MD), University of Auckland, Auckland, New Zealand; Clinical Hematology and Toxicology (K B Tran), Traute Wilkins Centre, Auckland, New Zealand; Department of Microbiology (I Ulliah PhD), Iqra National University, Peshawar, Pakistan; TB Culture Laboratory (I Ulliah), Mufi Mehmood Memorial Teaching Hospital, Dehla, Pakistan; Velez Sarsfield Hospital, Buenos Aires, Argentina (Prof P Valdez); Department of Medical and Surgical Sciences (Prof F S Violante MD), University of Bologna, Bologna, Italy; Occupational Health Unit (Prof F S Violante), Sant’Orsola Malpighi Hospital, Bologna, Italy; Department of Economics (Prof S Volliner), University of Göttingen, Göttingen, Germany; Foundation University Medical College (Prof Y Waheed PhD), Foundation University Islamabad, Islamabad, Pakistan; Department of Neurology (M T Wallin), George Washington University, Washington, DC, USA; Department of Epidemiology and Biostatistics (Yi Wang BSA, Prof C Yu PhD), Global Health Institute (Prof C Yu), School of Health Sciences (K G Zhao PhD), Wuhan University, Wuhan, China; Demographic Change and Aging Research Area (A Werdecker PhD), Center of Competence of Mortality-Follow-Up of the German National Cohort (Westeimer DSC), Federal Institute for Population Research, Wiesbaden, Germany; Center for Population and Health, Wiesbaden, Germany (A Werdecker); Department of Physical Therapy (T Wangkham MD), Naresuan University, Phitsanulok, Thailand; Department of Health Economics (G T Worku), Addis Continental Institute of Public Health, Addis Ababa, Ethiopia; Department of Orthopaedics (Prof A Wu MD), Wenzhou Medical University, Wenzhou, China; School of Medicine (Prof G Xu MD), Nanjing University, Nanjing, China; Clinical Cancer Research Center (S Yahyazadeh Jablani MD), Milad General Hospital, Tehran, Iran; Department of Public Health (Prof H Yatsu MD), Fujita Health University, Toyakake, Japan; Department of Public Health and Health Systems (Prof H Yatsu), Nagoya University, Nagoya, Japan; Pediatrics Department (C S Yilgwan MD), University of Jos, Jos, Nigeria; Department of Pediatrics (C S Yilgwan), Jos University Teaching Hospital, Jos, Nigeria; Centre for Suicide Research and Prevention (Prof P Yip PhD), Department of Social Work and Social Administration (Prof P Yip), University of Hong Kong, Hong Kong, China; Department of Neuropsychopharmacology (N Yonemoto MPH), National Center of Neurology and Psychiatry, Kodaira, Japan; Department of Public Health (N Yonemoto), Juntendo University, Tokyo, Japan; Department of Preventive Medicine (Prof S Yoon PhD), Korea University, Seoul, South Korea; Department of Health Policy and Management (Prof M Younis PhD), Jackson State University, Jackson, MS, USA; School of Medicine (Prof M Z Younis), Tsinghua University, Beijing, China; Department of Health Care Management and Economics (H Yusefzadeh PhD), Urmia University of Medical Science, Urmia, Iran; Department of Medicine (Prof Z Zaidi PhD), University Herfarth Abbas of Seifl, Sétif, Algeria; Department of Epidemiology and Public Health (N B Zepro), University of Basel, Basel, Switzerland; College of Medicine and Health Sciences (T A Zerfu), Dilla University, Dilla, Ethiopia; School of Public Health (Y Zhang PhD), Hubei Province Key Laboratory of Occupational Hazard Identification and Control (Y Zhang), Wuhan University of Science and Technology, Wuhan, China; School of Biology and Pharmaceutical Engineering (X G Zhao), Wuhan Polytechnic University, Wuhan, China; Health Technology Assessment Unit (Y H Zuniga BS), Department of Health Philippines, Manila, Philippines; #MentalHealthPH, Quezon City, Philippines (Y H Zuniga). Contributors P A Lindstedt, M M Baumann, and K E Wiens collected, cleaned, and vetted the data. K E Wiens provided estimates and K E Wiens, R C Reiner Jr, and A Deshpande vetted the models and the results. K E Wiens prepared the first draft of the manuscript. K E Wiens, K B Johnson, M M Baumann, and P A Lindstedt constructed the figures and tables. R C Reiner Jr and S I Hay provided overall direction and guidance. B F Blacker, K E Wiens, and R C Reiner Jr managed the project. K E Wiens, I E Schaeffer, M M Baumann, P A Lindstedt, and B F Blacker finalised the manuscript on the basis of comments from other authors and reviewer feedback. P A Lindstedt managed appendix I. M M Baumann and C A Welgan created appendix 2. All other authors provided data or developed models for indicators, reviewed results, initiated modelling infrastructure, or reviewed and contributed to the Article; their contributions can be found in appendix I (pp 158–162). Declaration of interests M L Bell reports grants from US Environmental Protection Agency, National Institutes of Health (NIH), and the Wellcome Trust Foundation, during the conduct of the study; and honoraria or travel reimbursement from NIH (for review of grant proposals), American Journal of Public Health (participation as editor). Global Research Laboratory and Seoul National University, Royal Society (London, UK), Ohio University, Atmospheric Chemistry Gordon Research Conference, Johns Hopkins, Bloomberg School of Public Health, Arizona State University, Ministry of the Environment, Japan, Hong Kong Polytechnic University, University of Illinois—Champaign, and University of Tennessee—Knoxville, outside of the submitted work. A Deshpande reports grants from Bill & Melinda Gates Foundation, during the conduct of the study. S M S Islam reports grants from National Heart Foundation of Australia, Institute for Physical Activity and Nutrition, and Deakin University, during the conduct of the study; and honoraria or travel reimbursement from National Institutes of Health (NIH), and the Wellcome Trust Foundation, during the conduct of the study. J J Jozwiak reports personal fees from Amgen, Zydus Cadilla, and personal fees from AstraZeneca, outside of the submitted work. J J Jozwiak reports personal fees from Amgen, ALAB Laboratory, Teva, Synexus, and Boehringer Ingelheim, outside of the submitted work. W Mendoza is a Program Analyst in Population and Development at the UN Population Fund Country Office in Peru, an institution which does not necessarily endorse this study. M J Postma holds stocks in Ingress Health and Pharmacoeconomics Advice Groningen and is advisor to Asc Academics, all pharmacoeconomics consultancy companies. M J Postma reports grants and personal fees from Merck Sharpe & Dohme, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Novavax, Bristol-Myer Squibb, AstraZeneca, Sanofi, IQVIA, Seqirus, Quintiles, Nocartis, and Pharmasset; grants from Bayer, BioMerieux, WHO, EU, FIND, Antilope, DIKTI, LPDP, and Budi; and other support from Ingress Health, Pharmacoeconomics Advice Groningen, and Asc Academics, outside of the submitted work. J A Singh reports personal fees from Creativa/Horizon, Medisys, Fidia, UBMB, Trio health, Medscape, WebMD, Clinical Care options, Clearview
Data sharing
The source code used to generate estimates is available online. The study data, including full sets of estimates at the first and second administrative levels, are available online.

Acknowledgments
This work was primarily supported by a grant from the Bill & Melinda Gates Foundation (OPP112415). L A Gure has received support from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001), Conselho Nacional de Desenvolvimento Científico e Tecnológico and Fundação de Amparo à Pesquisa do Estado de Minas Gerais. O O Adetokunboh acknowledges the South African Department of Science and Innovation and the National Foundation. S M Aljunid acknowledges the Department of Health Policy and Management, Faculty of Public Health, Kuwait University and International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia for the approval and support to participate in this research project. H T Atalay acknowledges Aksum University. M Auslos and C Herteliu are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNSD-UFEISCDI, project number PN-III-P1-1.2-PCCF-2016-0084. S F Azizparchi was supported by an Australian National Health and Medical Research Council (NHMRC) early career fellowship. A Badawi is supported by the Public Health Agency of Canada. T W Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research; the EU; the Wellcome Trust; and from National Institute of Child Health and Human Development of National Institutes of Health (NHI; R01-HD084233), National Institute on Aging of NHI (R01-AG042710), National Institute of Allergy and Infectious Diseases of NHI (R01-AI24389 and R01-AI112339), as well as for Fogarty International Center of NIH (D43-TW009775). G. B Britton is supported by Sistema Nacional de Investigación (SNI) de la Secretaría Nacional de Ciencia, Tecnología e Innovación (SINACYT) of Panama. A Barac is funded by the Project of Ministry of Education, Science and Technology of the Republic of Serbia (number 11450050). D A Bennett was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the UK Department of Health and Social Care. V M Costa acknowledges her grant (SFRH/BPD/110005/2015), received by Portuguese national funds through FCT/MEC and EU FEDER funds (project number PTDC/MCT/UI0056/2014). S M Islam is funded by a Fellowship from National Heart Foundation of Australia and Deakin University. M Jakovljevic and the Serbian part of this GBD contribution was co-funded through grant O17504 of the Ministry of Education, Science and Technological Development of the Republic of Serbia. A P Kengne is supported by the South African Medical Research Council.

Y J Kim's work was supported by the Research Management Centre, Xiamen University Malaysia, grants number XMUMRF/2018-C2/ ITCM/0001. Kris Kan is supported by a DST PURSE grant and UGC Center of Advanced Study awarded to the Department of Anthropology, Panjab University, Chandigarh, India. M Kumar acknowledges K43 TW010761-03. B Lacey acknowledges support from the NIH FRM Oxford Biomedical Research Centre and the British Heart Foundation Centre of Research Excellence, Oxford. P T N Menahau acknowledges School of Social Science, Humanities and Health Research in Africa. M Molokhia is supported by the NIHR Biomedical Research Center at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London. I Moreno Velasquez is supported by the Amadeus-Pereira Foundation, University of Medical Sciences for their wise advice. R Tabárés-Seisdedos was supported in part by grant PI17/00719 from Instituto de Salud Carlos III–FEDER. B Umukhran acknowledges Malapascua College of Higher Education, Cebu, Philippines. R R Weaver was supported by the Bill & Melinda Gates Foundation grant OPP1127433. C S Wijesinghe was supported by the South African Medical Research Council.

Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References